Richard Auchus, MD, PhD

Richard Auchus, MD, PhD


Professor of Pharmacology and Internal Medicine
Division of Metabolism, Endocrinology, and Diabetes 
University of Michigan School of Medicine
Ann Arbor, Michigan

Related Videos

Once the importance of uncoupling the androstenedione and glucocorticoid axes was understood, what targeting strategies were employed in the CAHtalyst trial that would lead to novel targeting of CRF1 with crinecerfont for CAH? Video

Once the importance of uncoupling the androstenedione and glucocorticoid axes was understood, what targeting strategies were employed in the CAHtalyst trial that would lead to novel targeting of CRF1 with crinecerfont for CAH?

What did the investigators of the CAHtalyst pediatric trial observe in the way of weight loss in children and adolescents? Was this a pre-specified secondary end point? Video

What did the investigators of the CAHtalyst pediatric trial observe in the way of weight loss in children and adolescents? Was this a pre-specified secondary end point?

What do you think are the most important clinical implications and learnings from the adult and pediatric CAHtalyst trials? Video

What do you think are the most important clinical implications and learnings from the adult and pediatric CAHtalyst trials?

Can you discuss the specifics of the adult CAHtalyst trial evaluating crinecerfont; and in what ways it was similar and in what ways did elements differ from the pediatric age group? Video

Can you discuss the specifics of the adult CAHtalyst trial evaluating crinecerfont; and in what ways it was similar and in what ways did elements differ from the pediatric age group?

How would you summarize the take-home lessons and translational implications of the CAHtalyst trials evaluating crinecerfont for CAH in adults and children? Video

How would you summarize the take-home lessons and translational implications of the CAHtalyst trials evaluating crinecerfont for CAH in adults and children?

Can you share with us how you became interested in CAH and what personal and discipline-related historical features have fueled your interest in advancing therapy for this disease state? Video

Can you share with us how you became interested in CAH and what personal and discipline-related historical features have fueled your interest in advancing therapy for this disease state?

Can you drill down to the specific parameters—inclusion criteria, glucocorticoid dosing, set points for androstenedione control, overall 2-part trial design—for the pediatric CAHtalyst trial? Video

Can you drill down to the specific parameters—inclusion criteria, glucocorticoid dosing, set points for androstenedione control, overall 2-part trial design—for the pediatric CAHtalyst trial?

Please discuss the two phases of the CAHtalyst trial in which you compared the placebo group with the crinecerfont arm, and the ability to maintain a down-titrated more physiological glucocorticoid dose. Video

Please discuss the two phases of the CAHtalyst trial in which you compared the placebo group with the crinecerfont arm, and the ability to maintain a down-titrated more physiological glucocorticoid dose.

Can you go into the specific end points for androstenedione, as well as your criteria for allowing progressive down-titration of glucocorticoid in phase 2 of the CAHtalyst trial? Video

Can you go into the specific end points for androstenedione, as well as your criteria for allowing progressive down-titration of glucocorticoid in phase 2 of the CAHtalyst trial?